Foundayo vs. the Wegovy Pill: How the Two GLP-1 Tablets Compare

For years the only way to take a GLP-1 drug for weight loss was a weekly injection. That changed in 2026. There are now two GLP-1 tablets approved in the United States for weight management: Novo Nordisk’s Wegovy pill (oral semaglutide 25 mg), which launched in January 2026, and Eli Lilly’s Foundayo (orforglipron), approved April 1, 2026 [1][6].

People searching “Foundayo vs Wegovy pill” usually want a winner. That is not an honest answer, because no randomized trial has ever compared them. What is available is a clear picture of how they differ, and those differences are real enough to matter to a decision you make with your doctor.

What is actually in each pill?

This is where everything else comes from.

The Wegovy pill is semaglutide — a peptide, a short chain of amino acids. Peptides get destroyed by stomach acid and digestive enzymes, so the tablet is formulated with an absorption enhancer to sneak the drug across the stomach lining. That trick only works in a narrow window, which is why the label imposes strict timing rules [2].

Foundayo is orforglipron — a non-peptide small molecule. It is ordinary chemistry, not biology. It survives the stomach on its own, so no enhancer and no timing rules are needed [1].

Both drugs switch on the same target, the GLP-1 receptor. Neither one touches the GIP receptor the way tirzepatide (Zepbound, Mounjaro) does.

How do you take each one?

This is the difference people feel every single day.

	Foundayo	Wegovy pill
Timing	Any time of day	Must be first thing, fasting
With food?	With or without food	Empty stomach only
Water limit	No limit stated	No more than 4 ounces of plain water
Wait before eating or drinking	None	At least 30 minutes
Other oral medicines	No timing rule stated	Wait at least 30 minutes
Tablet handling	Swallow whole, do not break, crush or chew	Swallow whole, do not split, crush or chew
Refrigeration	Not needed	Not needed

Sources: the Foundayo prescribing information [1] and the Wegovy prescribing information [2].

Lilly backed the “no restrictions” claim with a dedicated food-effect study. Taking orforglipron with food lowered total exposure by 19% and peak concentration by 26% versus fasting, with no change in timing or half-life, and the label concludes there is no clinically relevant food effect [1].

For a lot of people this is the whole decision. If you take a thyroid medicine first thing, or you have children to get out the door, or you simply know you will not remember a 30-minute fasted window every morning, the difference is not cosmetic.

Which one produces more weight loss?

Here is the honest version.

Foundayo’s pivotal trial, ATTAIN-1, enrolled 3,127 adults with obesity or overweight plus a weight-related condition and ran 72 weeks. At the highest dose, people who stayed on treatment lost an average of 12.4% of their body weight (27.3 pounds) — the efficacy estimand — versus 0.9% on placebo. Counting everyone regardless of whether they stayed on the drug, the New England Journal of Medicine reported 11.2%, roughly 25 pounds, versus 2.1%. At the top dose, 59.6% lost at least 10% and 39.6% lost at least 15% on the efficacy estimand; the FDA label’s intent-to-treat table prints 54.5% and 35.9% against 13% and 6% on placebo [1][3].

Novo Nordisk’s OASIS 4 trial of the 25 mg oral semaglutide tablet reported a higher average. Novo has been direct about the gap: in April 2026, one day after Foundayo’s approval, the company published an indirect comparison called ORION that pooled OASIS 4 and ATTAIN-1 data and adjusted for population differences. It reported that oral semaglutide 25 mg produced significantly greater mean weight loss than orforglipron at its top dose, and that orforglipron was associated with roughly 14 times higher odds of stopping treatment because of gastrointestinal side effects. A separate Novo survey reported 84% of respondents preferred a treatment profile resembling oral semaglutide [8].

Two things to hold in mind about ORION:

1. It is a manufacturer-sponsored indirect comparison, not a trial. It stitches together two studies that were run separately, with different participants, different sites and different lifestyle protocols. ATTAIN-1 in particular was, per Lilly, the first Phase 3 trial in this population run as an adjunct to exercise and a balanced healthy diet rather than a reduced-calorie diet [3]. Cross-trial adjustments cannot fully correct for that.
2. It is also the most rigorous public comparison that exists, and its direction is consistent with the raw headline numbers.

Novo’s US operations head, Jamey Millar, went further on approval day, saying that reports claiming orforglipron is more effective than the Wegovy pill were “inaccurate and misleading” [8].

Lilly has not published a rebuttal analysis in weight management. It has, however, published a real head-to-head in diabetes.

What happened when they were tested head to head?

ACHIEVE-3 is the only randomized Phase 3 trial that has ever put two oral GLP-1 receptor agonists against each other. It enrolled 1,698 adults with type 2 diabetes inadequately controlled on metformin and ran 52 weeks [4][5].

Endpoint at week 52	Oral semaglutide 7 mg	Oral semaglutide 14 mg	Foundayo 9 mg	Foundayo 17.2 mg
A1C change from 8.3%	-1.1%	-1.4%	-1.9%	-2.2%
Weight change from 213.9 lb	-3.7% (-7.9 lb)	-5.3% (-11.0 lb)	-6.7% (-14.6 lb)	-9.2% (-19.7 lb)
Reached A1C under 7%	54.6%	66.1%	80.0%	85.4%
Reached A1C under 5.7%	7.8%	12.5%	25.4%	37.1%
Stopped for side effects	4.5%	4.9%	8.7%	9.7%

Foundayo won on every efficacy endpoint, by a wide margin. Lilly framed it as a 57.1% greater relative A1C reduction and a 73.6% greater relative weight loss at the top-dose comparison [4].

But note what the comparator was. Oral semaglutide 7 mg and 14 mg are the approved diabetes doses, sold as Rybelsus. The Wegovy weight-management tablet is 25 mg, nearly double. ACHIEVE-3 tells you a lot about diabetes treatment choices and very little about which pill takes off more weight in someone without diabetes [4][5].

There is also a tolerability signal in that table worth carrying over: roughly twice as many people stopped Foundayo for side effects as stopped oral semaglutide, at doses that were not matched for potency.

What else is each pill approved to do?

This gap is bigger than the weight numbers and gets far less attention.

The Wegovy pill and injection are FDA-approved to reduce the risk of major cardiovascular events — cardiovascular death, heart attack and stroke — in adults with known heart disease and either obesity or overweight [2]. For someone with established heart disease, that is a distinct clinical reason to choose it.

Foundayo has no cardiovascular indication. Its outcomes trial, ATTAIN-Outcomes, enrolled 7,140 people starting in December 2025 and is not expected to finish until around 2031 [1]. Foundayo does have a favorable cardiovascular safety readout in people with type 2 diabetes from ACHIEVE-4, where it was non-inferior to insulin glargine on major adverse cardiovascular events, but non-inferiority to insulin is a safety finding, not a benefit claim.

Foundayo also has no approved diabetes indication in the US as of September 14, 2026. Lilly’s second-quarter 2026 earnings release, published August 5, 2026, lists the US type 2 diabetes submission for orforglipron among that quarter’s regulatory progress; the FDA has announced no decision [12]. The UK approved both indications on August 10, 2026.

How do the dose ladders compare?

Foundayo has six strengths — 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg — with a minimum of 30 days at each step and a maximum of 17.2 mg. Reaching the top takes at least five steps and about five months [1].

The Wegovy tablet reaches its 25 mg target dose in fewer steps [2].

Two practical consequences. First, a longer ladder means a longer stretch at lower doses before you know how well the drug works for you, and the trials show the low doses do less: ATTAIN-1’s 5.5 mg arm produced 7.8% weight loss versus 12.4% at 17.2 mg [3]. Second, Foundayo’s label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose escalation — with six strengths, that can add up to several separate windows [1]. The label notes this effect has not been evaluated in a clinical trial.

What about side effects?

Both drugs produce the same family of gastrointestinal effects: nausea, constipation, diarrhea, vomiting, indigestion, burping and abdominal pain, mostly during dose escalation and mostly mild to moderate.

In the pooled Foundayo trials, nausea affected 26% to 35% of people depending on dose versus 10% on placebo; constipation 20% to 27% versus 9%; diarrhea 21% to 25% versus 11%; vomiting 13% to 24% versus 4%. Overall, 8% of Foundayo patients stopped permanently because of adverse reactions, versus 3% on placebo [1].

Both carry the same boxed warning for thyroid C-cell tumors and the same contraindications for people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1][2]. Our Foundayo side effects guide goes through the full label.

One Foundayo-specific consideration: because orforglipron is cleared by the liver enzyme CYP3A4, it has drug interactions that injectable peptides do not. The label caps Foundayo at 9 mg with a strong CYP3A4 inhibitor, says to avoid strong inducers, and caps simvastatin at 20 mg [1]. If you take several medicines, that is worth raising with your pharmacist.

Which one are people actually taking?

The Wegovy pill, by a large margin so far.

Novo Nordisk announced on June 7, 2026 that the Wegovy pill had passed 3 million US prescriptions in just over five months, and said more than 80% of new prescriptions were going to people new to GLP-1 therapy [7]; by the company’s second-quarter reporting that figure had passed 5 million since the January launch [11]. Weekly prescription data compiled by Fierce Pharma from IQVIA figures cited by Citi and Jefferies show the gap plainly. In the week reported on September 4, 2026 — the most recent update this article could verify — the Wegovy pill was at roughly 181,000 weekly prescriptions and Foundayo at about 44,000, both record highs [6]. Foundayo’s climb over the preceding month ran 26,760, 29,388, 34,219 and about 40,900 before that reading [6].

Those are total prescriptions from one panel. A second panel, Symphony Health, circulating in investor communities over the same period put Foundayo far lower — around 17,700 against roughly 143,000 for the Wegovy pill — because the two panels capture different pharmacy and channel mixes. Both agree on direction and on the Wegovy pill’s lead; they disagree on Foundayo’s absolute level by more than a factor of two. The two should never be mixed in one comparison.

Two caveats. The Wegovy pill launched about three months earlier and had full insurance coverage from its first week, while Foundayo did not get CVS Caremark coverage until June 1, 2026 [6]. And Citi has repeatedly warned that IQVIA data may undercount prescriptions written through telehealth, which matters more for a newer brand [6].

Both launches together did something notable: Citi attributed a swing in total GLP-1 prescription growth, from a 6.8% decline a year earlier to a 5.4% four-week increase, to the arrival of oral GLP-1s pulling new patients into the category [6].

What about cost?

For most people, insurance decides this, not the sticker.

• Commercial insurance that covers the drug: both manufacturers advertise as little as $25 a month (verified 2026-09-14) with a savings card, with caps. This is a savings-card tier that requires the plan to cover the drug, not a cash price. Lilly’s Foundayo card caps savings at $100 per one-month fill and $1,000 per calendar year, allows up to 10 fills a year, and expires December 31, 2026 [9].
• Medicare Part D: both Foundayo tablets and Wegovy tablets and injection are covered by the Medicare GLP-1 Bridge at a flat $50 monthly copay for people who meet CMS’s clinical criteria. The program started July 1, 2026 and runs through December 31, 2027. The copay does not count toward your Part D deductible or out-of-pocket cap [10].
• Self-pay: Lilly’s published ladder is $149 a month for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg — point prices per dose, not a range. Through December 31, 2026 the 2.5 mg dose is temporarily $149 and 5.5 mg is temporarily $199, and a 45-day refill program holds the top two doses at $299 [9]. Behind the ladder, Lilly’s published list price (wholesale acquisition cost) for Foundayo is $649 for a 30-day supply at every strength [13]. Novo prices its self-pay programs separately and changes terms often; its published list price for Wegovy tablets was not re-verified for this page, so no figure for it is given here.

Our full Foundayo cost guide breaks down every route.

So which should you ask about?

There is no universal answer, and any page that gives you one is guessing. What the evidence supports:

• If daily practicality is your sticking point — you will not manage a fasted 30-minute window — Foundayo’s label is genuinely easier to live with, and that is a real clinical advantage because a drug you skip does not work.
• If maximum average weight loss from a pill is the priority, the available data, imperfect as they are, point toward the 25 mg Wegovy tablet.
• If you have established heart disease, only the Wegovy pill carries an approved cardiovascular risk-reduction indication.
• If you are managing type 2 diabetes and your provider is choosing between oral GLP-1s, ACHIEVE-3 is the one genuinely randomized comparison and it favored Foundayo on A1C and weight, at the cost of more side-effect discontinuations.
• If you take several other medicines, Foundayo’s CYP3A4 interactions deserve a specific conversation with your pharmacist.

Bring this list to your healthcare provider rather than a conclusion. They know your history, your other prescriptions and your plan’s formulary, which is what actually decides it.

Sources

1. FOUNDAYO (orforglipron) tablets — US Prescribing Information, rev. 7/2026, Eli Lilly and Company
2. WEGOVY (semaglutide) — US Prescribing Information, Novo Nordisk
3. Complete ATTAIN-1 results published in the New England Journal of Medicine — Eli Lilly and Company, September 16, 2025
4. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head trial — Eli Lilly and Company, February 26, 2026
5. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) — The Lancet, 2026
6. The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb — Fierce Pharma, September 11, 2026
7. Wegovy pill prescriptions surpass 3 million — Novo Nordisk, June 7, 2026
8. Novo Nordisk media release on the ORION indirect treatment comparison, April 2, 2026
9. Foundayo Coverage & Savings — Eli Lilly and Company
10. Medicare GLP-1 Bridge — Centers for Medicare & Medicaid Services
11. How cost and perception could reshape the GLP-1 market — BioPharma Dive, 2026
12. Lilly reports second-quarter 2026 financial results — Eli Lilly and Company, August 5, 2026
13. Foundayo cost information: list price (WAC) — Lilly Pricing Info, Eli Lilly and Company